Business
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL. The poster will include clinical d
About this update from Zentalis Pharmaceuticals, Inc.
[{"type":"image","alt":"ZENTALIS PHARMACEUTICALS","displaySize":"","headline":null,"caption":"ZENTALIS PHARMACEUTICALS","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/8a2329194a3b92e9d92b6dddf1b01631"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nQzP_GawPdWO8YMImzkdkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8a2329194a3b92e9d92b6dddf1b01631","width":300,"height":87}},"lazy":false},{"type":"text","content":"SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL.","length":465,"tagName":"p"},{"type":"text","content":"The poster will include clinical data as of an April 4, 2025 data cutoff from the Company’s ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant colorectal cancer.","length":258,"tagName":"p"},{"type":"text","content":"Abstract and poster presentation details are below:","length":51,"tagName":"p"},{"type":"text","content":"Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with previously treated BRAF V600E mutant metastatic colorectal cancer”Abstract Number: 3551Poster Session: Gastrointestinal Cancer – Colorectal and Anal Poster Board: 372Date/Time: Saturday, May 31, 2025, 9:00 a.m. - 12:00 p.m. CDTPresenter: Dr. Jeanne Tie","length":396,"tagName":"p"},{"type":"text","content":"The poster can be accessed through the “Supporting Publications” tab on the “Our Approach” section of the Zentalis website on the day of the presentation.","length":154,"tagName":"p"},{"type":"text","content":"About Azenosertib","length":17,"tagName":"p"},{"type":"text","content":"Azenosertib is a novel, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated as a monotherapy and combination clinical studies in ovaria...